Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Insights into the Metabolic Control of RA T Cells

Lara C. Pullen, PhD  |  October 30, 2017

T cells cause autoimmune damage when they traffic to peripheral tissues and maneuver within them. Although T cells may first appear to walk randomly to infiltrate a tissue, pathogenic T cells must form organized membrane extensions for directed motion. This process appears to be critical for rheumatoid arthritis  (RA) pathogenesis, because joint-invading T cells must be able to rapidly enter the synovial membrane and penetrate joint tissue. The cells must then travel through extravascular space and transform into proinflammatory RA effector cells.

Scientists can differentiate these effector T cells from naïve cells by their metabolic pathways. Proliferating naive cells are glycolysis dependent, but this dependence changes as the cells acquire effector functions. In particular, RA effector T cells are reprogrammed to shunt glucose away from glycolysis and toward the pentose-phosphate pathway. New research from Stanford University School of Medicine in California and the Mayo Clinic College of Medicine in Rochester, Minn., suggests that metabolic control of T cell locomotion may provide an intervention, preventing T cells from invading specific tissue sites. Yi Shen of Stanford and colleagues published their research in the September issue of Nature Immunology.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers began by examining the migratory capacity of RA and healthy, human-activated naive CD4+ T cells in a chemokine-free system. They compared the two groups of cells to identify differences in the expression of a core group of genes associated with cellular locomotion.

The investigators identified the aberrant expression of the podosome scaffolding protein TKS5 in patient-derived T cells. When they examined whether those cells would be more likely to invade chimeric mouse tissue than control cells, they found these RA T cells formed membrane ruffles that allowed them to spread and move into non-lymphoid tissues. The RA T cells also had aberrant lipid biosynthesis. Specifically, the researchers found markedly higher concentrations of 20 lipogenesis genes in the patients relative to controls. When they activated RA T cells in vitro, they found higher levels of ACACA, FASN and SCD transcripts—all of which are required for de novo synthesis of fatty acids—in these patient cells compared with activated control cells. Researchers note that not all genes related to intracellular lipid homeostasis were affected when the RA T cells shunted toward lipid anabolism. The broad lipogenic gene program seen in activated RA T cells was selective and focused on the formation of fatty acids and cytoplasmic lipid droplet, but not cholesterol.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“RA T cells are distinguished from their healthy counterparts by dampened glycolytic breakdown, reduced pyruvate production and accelerated [pentose-phosphate pathway] shunting,” explain the authors in their discussion. “Instead of adopting a primarily catabolic program, they utilize anabolic biosynthesis.”

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsRheumatoid Arthritis Tagged with:metabolicRheumatoid Arthritis (RA)T cell

Related Articles

    Diagnosis: Myopathy

    July 1, 2009

    Presentation and evaluation of metabolic causes

    AJPhoto / Science Source

    Tips for Diagnosing Metabolic Myopathies

    September 17, 2019

    When evaluating patients with possible myopathic symptoms, rheumatologists must consider a rare, but important, group of inherited disorders: the metabolic myopathies. However, their diagnosis often remains a challenge. Early recognition of these primary metabolic myopathies is essential to help prevent disease morbidity and mortality from rhabdomyolysis. Here, we focus on the metabolic myopathies that present…

    How Energy Shifts Lead to Systemic Illness

    July 12, 2011

    The impact of adaptive energy programs on the manifestations of chronic inflammatory disease

    What Fat Does to Arthritis

    August 1, 2011

    The role of adipokines in the pathogenesis of rheumatic diseases

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences